Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1Breast Diseases 1

Interventions

pembrolizumab 42Specimen Handling 38Magnetic Resonance Spectroscopy 30Carboplatin 30Cyclophosphamide 27Biopsy 25Nivolumab 23Dexamethasone 22fludarabine 21Gemcitabine 19Bevacizumab 15Paclitaxel 14Temozolomide 13Pemetrexed 13Docetaxel 13Cisplatin 13atezolizumab 12Ipilimumab 12Rituximab 11venetoclax 10Prednisone 10Lenalidomide 9Injections 9Fulvestrant 9lenvatinib 8X-Rays 8Vincristine 8Trastuzumab 8Oxaliplatin 8Fluorouracil 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Imlunestrant × 30 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡